Non-Cystic Fibrosis Bronchiectasis Market
The Non-Cystic Fibrosis Bronchiectasis market across the 7MM was valued at approximately USD 1,487 million in 2025 and is projected to reach approximately USD 5,768 million by 2034. Over the forecast period from 2025 to 2034, the Non-Cystic Fibrosis Bronchiectasis market is expected to expand at a CAGR of 16.25% across leading countries including the US, EU4, UK, and Japan, reflecting strong momentum fueled by growing disease awareness, improved diagnostics, and an increasingly active therapeutic pipeline.
Non-Cystic Fibrosis Bronchiectasis Disease Understanding
NCFB is a chronic inflammatory lung condition characterized by irreversible bronchial dilation, resulting in persistent sputum production and compromised bacterial clearance. This dysfunction establishes a detrimental cycle where ineffective pathogen elimination leads to recurrent infections, chronic inflammation, and progressive pulmonary damage. Symptoms commonly include cough, excessive sputum production, and frequent respiratory infections, alongside shortness of breath, wheezing, hemoptysis, and chest pain.
Severity varies considerably among individuals – some experience mild, sporadic episodes while others endure daily, debilitating symptoms, often exacerbated by infectious triggers. NCFB is frequently associated with comorbidities like anxiety, depression, and fatigue, which significantly diminish patients’ quality of life and contribute to longer hospital stays and increased outpatient visits. Its etiology is multifaceted, with a considerable proportion of cases attributed to idiopathic factors, post-infective complications, and associations with conditions such as COPD and asthma, underscoring the complexity of its management.
Download the full market report to explore in-depth forecasts, pipeline analysis, and competitive landscape for Non-Cystic Fibrosis Bronchiectasis.
Non-Cystic Fibrosis Bronchiectasis Diagnosis
The diagnosis of NCFB is primarily established through chest computed tomography scans, which provide detailed imaging of bronchial dilation and associated abnormalities. Complementary modalities – including chest X-rays, bronchoscopy, lung function tests, blood tests, and sputum cultures – are utilized to identify underlying conditions and assess microbial colonization. Given the heterogeneous nature of bronchiectasis and its multifactorial origins, no single diagnostic measure can comprehensively evaluate disease severity or prognosis. To address this complexity, two validated scoring systems – the Bronchiectasis Severity Index (BSI) and the FACED score – are employed to systematically assess disease severity, enabling more nuanced and individualized management strategies.
Non-Cystic Fibrosis Bronchiectasis Treatment
The Non-Cystic Fibrosis Bronchiectasis treatment landscape is focused on symptom management, slowing the decline in lung function, and preventing exacerbations. Chest physiotherapy remains a cornerstone of management due to its effectiveness and minimal side effects, while some patients derive additional benefit from prophylactic low-dose macrolides. The current treatment regimen encompasses antibiotics, corticosteroids, bronchodilators, acid suppression medications, mucolytic agents, and strategies to enhance bronchial hygiene.
Non-Cystic Fibrosis Bronchiectasis clinical trials are actively investigating new antibiotics, anti-inflammatory agents, and airway clearance therapies to improve patient outcomes. Elevated neutrophil levels in the airways highlight the potential of anti-inflammatory therapies such as corticosteroids and macrolides. However, the heterogeneity of NCFB necessitates a personalized treatment approach, as existing therapies can be labor-intensive and may induce side effects, contributing to rising resistance. This complexity underscores the critical need for novel drug development to provide more effective and streamlined options tailored to individual patient profiles.
Non-Cystic Fibrosis Bronchiectasis Epidemiology
According to DelveInsight’s patient-based epidemiology model, the following key findings characterize the NCFB burden across the 7MM:
- Total diagnosed prevalent cases of NCFB in the 7MM were approximately 1,028,651 in 2023, expected to rise through 2034 driven by increased awareness and improved diagnostics
- The US accounted for the highest diagnosed prevalent cases – approximately 380,711 in 2023; France had the least, with approximately 37,576 cases
- Among EU4 and the UK, the UK led with approximately 224,976 cases in 2023, followed by Spain (~149,236) and Italy (~89,584)
- Severity-specific cases in EU4 and the UK in 2023: approximately 235,481 moderate, ~163,649 severe, and ~152,230 mild cases
- Gender-specific cases in the UK in 2023: approximately 130,486 female and ~94,490 male cases
- In Japan, the majority of etiology-specific cases were attributed to unknown or idiopathic causes (~32,837 cases), with total diagnosed prevalent cases of approximately 96,580 in 2023
Leading Non-Cystic Fibrosis Bronchiectasis Companies
The leading Non-Cystic Fibrosis Bronchiectasis companies developing therapies include Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others, each advancing differentiated therapeutic candidates across various stages of clinical development.
Non-Cystic Fibrosis Bronchiectasis Recent Developments
- August 2025: The FDA approved Insmed’s BRINSUPRI (brensocatib) – the first oral therapy for NCFB in patients 12 years and older. Insmed set the annual price at $88,000 before discounts
- February 2025: Insmed announced FDA acceptance of its New Drug Application (NDA) for brensocatib for NCFB patients, with Priority Review granted and a PDUFA target action date of August 12, 2025
- October 2024: Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib at the CHEST 2024 Annual Meeting
Marketed Non-Cystic Fibrosis Bronchiectasis Drugs
BRINSUPRI (brensocatib) – Insmed
Brensocatib is an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs) – such as neutrophil elastase – during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with NCFB, leading to an NDA submission to the US FDA in late 2024. In August 2025, the FDA approved BRINSUPRI (brensocatib) as the first oral therapy for NCFB in patients 12 years and older.
Emerging Non-Cystic Fibrosis Bronchiectasis Drugs
Inhaled Colistimethate Sodium (CMS I-neb) – Zambon
CMS I-neb is an investigational inhaled therapy for adults with NCFB colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin – a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for difficult infections. In September 2024, Zambon released Phase III PROMIS-I and PROMIS-II study results in The Lancet Respiratory Medicine. PROMIS-I demonstrated a significant reduction in pulmonary exacerbation rates; PROMIS-II, terminated early due to the pandemic, showed pre-pandemic data consistent with PROMIS-I outcomes. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), QIDP, and Fast Track Designation (FTD).
FASENRA (benralizumab) – AstraZeneca
FASENRA (benralizumab) is a monoclonal antibody targeting the IL-5 receptor alpha on eosinophils, facilitating natural killer cell recruitment to induce apoptosis – resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with Non-Cystic Fibrosis Bronchiectasis associated with eosinophilic inflammation (NCFB + EI). According to ClinicalTrials.gov, FASENRA completed Phase III clinical trials for this indication in April 2024.
Non-Cystic Fibrosis Bronchiectasis Drugs Analysis
The Non-Cystic Fibrosis Bronchiectasis treatment involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics – both oral and inhaled – are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides are broadly used for their anti-inflammatory properties to reduce exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids address inflammation, albeit with limitations due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation – such as DPP1 inhibitors – represent innovative approaches. The Non-Cystic Fibrosis Bronchiectasis market research highlights that together, these drug classes form a comprehensive yet evolving treatment landscape for NCFB, addressing its multifaceted pathophysiology, with demand for effective antibiotic and anti-inflammatory treatments continuing to rise alongside growing prevalence.
Non-Cystic Fibrosis Bronchiectasis Market Outlook
The market for NCFB is poised for significant growth, driven by the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass antibiotics, corticosteroids, bronchodilators, and mucolytics, with inhaled antibiotics demonstrating particular efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies such as brensocatib (a DPP1 inhibitor) and BI 1291583 (a cathepsin C inhibitor) target neutrophilic inflammation through distinct mechanisms. Investigational therapies including CMS I-neb and monoclonal antibodies such as FASENRA and Itepekimab further expand the pipeline by directly targeting specific inflammatory pathways. Airway Clearance Techniques (ACTs) complement pharmacological regimens, enhancing mucus clearance and preventing infection.
Non-Cystic Fibrosis Bronchiectasis market trends underscore some ongoing challenges – including a lack of consensus guidelines and under-researched therapies like mucolytics and hyperosmolar agents – which may hinder optimal patient management. Nevertheless, the
Non-Cystic Fibrosis Bronchiectasis market insight from ongoing clinical trials reflects a promising pipeline that could fill critical gaps in NCFB management.
Key market figures:
- The 7MM market was valued at approximately USD 1,487 million in 2025, anticipated to grow to approximately USD 5,768 million by 2034, at a CAGR of 16.25%
- The US market was approximately USD 664.3 million in 2023, accounting for ~46% of the 7MM total
- The EU4 and UK market was approximately USD 722.9 million in 2023; the UK led at ~USD 295.0 million, followed by Spain (~USD 195.7 million) and Italy (~USD 117.5 million)
- The Japan market was approximately USD 67.8 million in 2023
- Bronchodilators held the majority of Non-Cystic Fibrosis Bronchiectasis Market Share, with revenue of approximately USD 1,010.8 million in 2023 across the 7MM
Request a free sample today and unlock comprehensive insights driving the Non-Cystic Fibrosis Bronchiectasis market.
Conclusion
The Non-Cystic Fibrosis Bronchiectasis market is entering a period of substantial expansion, supported by rising disease prevalence, enhanced diagnostic capabilities, and increasing awareness among healthcare providers and patients. The approval of innovative therapies such as BRINSUPRI and the advancement of promising pipeline candidates are transforming the treatment landscape and addressing significant unmet medical needs. Growing investments in research, targeted anti-inflammatory therapies, and inhaled antibiotics are expected to improve patient outcomes while expanding commercial opportunities. With a projected CAGR of 16.25% through 2034, the market is well-positioned for sustained growth across the US, Europe, and Japan, driven by continuous therapeutic innovation.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
